Entity

Time filter

Source Type

Oxton, United Kingdom

Patent
Chroma Therapeutics | Date: 2010-12-01

Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers:


Patent
Chroma Therapeutics | Date: 2011-12-16

An imaging agent for cells which produces an intracellular imaging signal proportional to the amount of hCE-1 in the cells independently of the amount of hCE-2 and/or hCE-3 in the cells, said imaging agent being a covalent conjugate of (a) an imaging agent and (b) an alpha mono- or di-substituted amino acid ester, wherein (a) is directly linked to (b), or (a) is indirectly linked to (b) by a linker radical, and wherein said direct or indirect linkage is via the amino group of (b), and wherein the amino group is not directly linked to a carbonyl group, and wherein the said alpha mono- or di-substituted amino acid ester part is selectively hydrolysable to the corresponding carboxylic acid part by the intracellular carboxylesterase enzyme hCE-1 relative to the intracellular enzymes hCE-2 or hCE-3.


Patent
Chroma Therapeutics | Date: 2010-02-25

Compounds of formula (I), inhibit HDAC activity: wherein A, B and D independently represent CH or N; W is CHCH Or CH


Patent
Chroma Therapeutics | Date: 2014-02-13

Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R


Patent
Chroma Therapeutics | Date: 2010-04-20

The invention provides a compound which is (a) a thiophene carboxamide derivative of formula (IA) or (IB), or a tautomer thereof; or (b) a pharmaceutically acceptable salt, N-oxide, hydrate or solvate thereof, wherein L

Discover hidden collaborations